These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33010699)

  • 1. Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer.
    Zhang H; Wang Y; Wang Y; Wu D; Lin E; Xia Q
    Pathol Res Pract; 2020 Nov; 216(11):153229. PubMed ID: 33010699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks.
    Ge X; Wang H; Zeng H; Jin X; Sujie A; Xu C; Liu Y; Huang J; Ji Y; Tan Y; Liu T; Hou Y; Qin J; Sun Y; Qin X
    Hum Pathol; 2015 Jun; 46(6):850-7. PubMed ID: 25863425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
    Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
    Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case.
    Saito T; Kondo C; Shitara K; Ito Y; Saito N; Ikehara Y; Yatabe Y; Yamamichi K; Tanaka H; Nakanishi H
    Pathol Int; 2015 Jun; 65(6):309-17. PubMed ID: 25828363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 assessment in locally advanced gastric cancer: comparing the results obtained with the use of two primary tumour blocks versus those obtained with the use of all primary tumour blocks.
    Xu C; Liu Y; Jiang D; Ge X; Zhang Y; Su J; Zeng H; Huang J; Ji Y; Hou J; Sun Y; Shen K; Liu T; Hou Y; Qin J
    Histopathology; 2017 Oct; 71(4):570-579. PubMed ID: 28513868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
    Nishida Y; Kuwata T; Nitta H; Dennis E; Aizawa M; Kinoshita T; Ohtsu A; Ochiai A
    Gastric Cancer; 2015 Jul; 18(3):458-66. PubMed ID: 24917219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
    Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
    World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
    Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
    Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer.
    Tominaga N; Gotoda T; Hara M; Hale MD; Tsuchiya T; Matsubayashi J; Kono S; Kusano C; Itoi T; Fujimoto K; Moriyasu F; Grabsch HI
    Gastric Cancer; 2016 Apr; 19(2):553-560. PubMed ID: 25987463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
    Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
    Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 in resected gastric cancer: Is there prognostic value?
    Fisher SB; Fisher KE; Squires MH; Patel SH; Kooby DA; El-Rayes BF; Cardona K; Russell MC; Staley CA; Farris AB; Maithel SK
    J Surg Oncol; 2014 Feb; 109(2):61-6. PubMed ID: 24122802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human epidermal growth factor receptor 2 overexpression in gastric and gastroesophageal junction adenocarcinoma in patients seen at the University Teaching Hospital, Lusaka, Zambia.
    Kasochi C; Julius P; Mweemba I; Kayamba V
    Afr Health Sci; 2020 Dec; 20(4):1857-1864. PubMed ID: 34394249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
    Shan L; Ying J; Lu N
    Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer.
    Zhang XL; Yang YS; Xu DP; Qu JH; Guo MZ; Gong Y; Huang J
    World J Surg; 2009 Oct; 33(10):2112-8. PubMed ID: 19636613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical Human Epidermal Growth Factor Receptor 2 (HER2) Expression Pattern in Gastric Adenocarcinomas in a Nigerian Tertiary Hospital.
    Mashor MI; Ezenkwa US; Ogun GO; Ajani MA; Ogunbiyi JO
    West Afr J Med; 2024 Mar; 41(3):311-316. PubMed ID: 38788150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens.
    Yang J; Luo H; Li Y; Li J; Cai Z; Su X; Dai D; Du W; Chen T; Chen M
    Cell Biochem Biophys; 2012 Jan; 62(1):221-8. PubMed ID: 21927816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low frequency of HER2 amplification and overexpression in early onset gastric cancer.
    Moelans CB; Milne AN; Morsink FH; Offerhaus GJ; van Diest PJ
    Cell Oncol (Dordr); 2011 Apr; 34(2):89-95. PubMed ID: 21394646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2, NF-
    Smolińska M; Grzanka D; Antosik P; Kasperska A; Neska-Długosz I; Jóźwicki J; Klimaszewska-Wiśniewska A
    Dis Markers; 2019; 2019():6315936. PubMed ID: 31737131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.
    Lee HE; Park KU; Yoo SB; Nam SK; Park DJ; Kim HH; Lee HS
    Eur J Cancer; 2013 Apr; 49(6):1448-57. PubMed ID: 23146959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing: A Direct Comparison Study with Immunohistochemistry.
    Choi S; Chu J; Kim B; Ha SY; Kim ST; Lee J; Kang WK; Han H; Sohn I; Kim KM
    J Mol Diagn; 2019 Jul; 21(4):612-622. PubMed ID: 31022472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.